WORLDSymposium™ 2020 Preliminary Program* on Lysosomal Diseases
The preliminary program for WORLDSymposium 2020 will be posted by the end of November, 2019.
WORLDSymposium has become the major educational and unifying activity of Lysosomal Disease Researchers, and has evolved into a highly interactive research activity. The underlying theme “transitioning molecular biology to human therapies” seeks to elucidate the challenges—and highlight the successes—in bringing bench discoveries into successful clinical therapies.
The main emphasis of the meeting remains the same: to assess the mechanisms, and obstacles, for taking bench research into human therapy.
The first day of the Symposium research program is focused on basic research, the second day on translational research, and the third on clinical research. This day-by-day progression through the three stages of research is a signature feature of WORLDSymposium and is enthusiastically received based on attendee evaluation.
Basic and bench research (Monday afternoon, Tuesday morning). Following the Young Investigator Awards, presentations in the afternoon session will discuss innovations in technology and how they can be applied to early diagnosis for lysosomal conditions, progress in gene therapy, and exploitation of differences at the cellular level that may indicate early disease state. Basic and bench research presentations continue Day 2: Tuesday morning starting with Roscoe O. Brady Award for Innovation and Accomplishment.
Translational research – Newborn Screening (Tuesday afternoon). Presentations in this afternoon session turn to the challenge of moving laboratory discoveries to therapy, the important hurdles of translational research. Some broad topics of discussion include modulation of CNS affects of disease, how to increase the efficacy of therapeutic modalities, and genotype/phenotype correlations.
Translational research – Gene Therapy (Wednesday morning). The fourth day of the meeting continues the discussion of the challenge of moving laboratory discoveries to therapy, the important hurdles of translational research. Some broad topics of discussion include modulation of CNS affects of disease, how to increase the efficacy of therapeutic modalities, and genotype/phenotype correlations.
Clinical research (Wednesday afternoon, Thursday morning). These sessions are committed to presentations of results from clinical trials, in most cases, the actual application of new agents in humans affected by these conditions. These sessions will include presentations related to re-thinking the definition of biomarkers for lysosomal disease.
The daily sessions of the meeting conclude at 4:30 PM.
*This will be a preliminary program only. ALL times and speakers will be subject to change. Be sure to check back weekly as updates are made.
Attention to All Platform Speakers: It is the policy of WORLDSymposium to publish all abstracts with the list of authors exactly as the abstract was submitted to WORLDSymposium. The first author of the submitted abstract will be listed as the Platform Speaker (presenting author) on the Preliminary Program, Agenda, and Poster List.
All requests for changes to the Platform Speaker (presenting author) will be reviewed by the WORLDSymposium Planning Committee prior to approval. No changes will be made to the Preliminary Program posted online; any changes to the Platform Speaker will be announced from the podium by the co-chairs only at the time of the platform presentation. The Preliminary Program will remain published with the original first author, and all communication will continue to go to the first author of the abstract.
The submitting first author will continue to receive all instructions from the automated abstract notification system. Please be sure that the first author is aware they will need to forward any email instructions for PowerPoint preparation, and for advance review of presentations. Meeting the presentation guidelines and submitting presentations for prior review must be done to meet ACCME accreditation requirements.
Reference the Frequently Asked Questions pages for additional information.